NCT06992609
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06992609
Title Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer. (ALBORAN)
Acronym ALBORAN
Recruitment Not yet recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications
Therapies
Age Groups: adult | senior
Covered Countries ESP


No variant requirements are available.